Wyss Institute launches ReadCoor to commercialize 3D in situ gene sequencing technology

New startup will leverage a method for simultaneously sequencing and mapping thousands of RNAs within cells and tissues

Boston, Mass. – The Wyss Institute for Biologically Inspired Engineering at Harvard University today announced that its FISSEQ (fluorescent in situ sequencing) technology will be commercialized by a newly formed company, ReadCoor, Inc.

FISSEQ is a spatial gene sequencing technology that simultaneously reads the sequences of thousands of RNAs — the working copies of genes — and visualizes their three-dimensional coordinates within whole cells and tissues, a capability that stands to revolutionize clinical diagnostics and drug discovery. ReadCoor has entered into a worldwide licensing agreement with Harvard’s Office of Technology Development, securing the exclusive right to market FISSEQ technology.

“FISSEQ reveals the dimensional context of molecular interactions inside cells and tissues underpinning both healthy tissue development and the changes that bring about dise

< | >